Dynamic variability of hemostatic and fibrinolytic factors in young women

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 12, 2004, Pages 6179-6184

  Giardina, Elsa Grace V ^a,b   Chen, Hong Jun ^a   Sciacca, Robert R ^a   Rabbani, Leroy E ^a  

^a Columbia Univ Coll Phys Surgs ^*  (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; D DIMER; ESTRADIOL; FIBRINOGEN; FIBRINOLYTIC AGENT; FOLLITROPIN; HEMOSTATIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; FEMALE; FOLLICULAR PHASE; HEMOSTASIS; HORMONE BLOOD LEVEL; HUMAN; LUTEAL PHASE; MENSTRUAL CYCLE; NORMAL HUMAN; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; BODY MASS INDEX; CORONARY DISEASE; ESTRADIOL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; FOLLICLE STIMULATING HORMONE; FOLLICULAR PHASE; HEMOSTASIS; HORMONES; HUMANS; LIPIDS; LUTEAL PHASE; OSMOLAR CONCENTRATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 10344256706     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-0598     Document Type: Article

References (43)

1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the HERS Research Group 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613
2. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N, HERS Research Group 2002 Cardiovascular disease outcomes during 6.8 years of HRT: HERS follow-up. JAMA 288:49-57
3. The Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled study. JAMA 288:32321-32333
4. Ridker P, Hennekens C, Rifai N, Buring JE, Manson JE 1999 Hormone replacement therapy and increased plasma concentration of C-reactive protein. Circulation 100:713-716
5. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP 1999 Effect of postmenopausal hormones on inflammatory-sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEPI) study. Circulation 100:717-722
6. Rabbani LE, Seminario NA, Sciacca RR, Chen HJ, Giardina EGV 2002 Conjugated oral estrogen increases plasma von Willebrand factor levels in post-menopausal women. J Am Coll Cardiol 40:1991-1999
7. Lip GYH, Blann AD 2000 Thrombogenesis and fibrinolysis in acute coronary syndromes. J Am Coll Cardiol 36:2044-2046
8. Stec JJ, Silbershatz H, Tofler GH, Matheney TH, Sutherland P, Lipinska I, Massaro JM, Wilson PF, Muller JE, D'Agostino Sr RB 2000 Association of fibrinogen with cardiovascular risk factor and cardiovascular disease in the Framingham offspring population. Circulation 102:1634-1638
9. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK 2001 Prospective study of fibrinolytic factors and incident coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21:611-617
10. Thogersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G 1998 High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98:2241-2247
11. Bounameaux H, Kruithof E 2000 On the association of elevated tPA/PAI-1 complex and von Willebrand factor with recurrent myocardial infarction. Arterioscler Thromb Vasc Biol 20:1857-1859
12. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U 2000 Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEP) study. Arterioscler Thromb Vasc Biol 20:2019-2023
13. Johansson L, Jansson JH, Boman K, Nilsson TK, Stegmayr B, Hallmaans G 2000 Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 31:26-32
14. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ 1997 von Willebrand factor and factor VIII:C in acute cerebrovascular disease: relationship to stroke, subtype and mortality. Thromb Haemost 77:1104-1108
15. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon RO 1997 Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336:683-690
16. Scarabin P-Y, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M 1997 Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 17:3071-3078
17. Lip GYH, Blann AD, Jones AF, Gareth Beevers D 1997 Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Am Heart J 134:764-771
18. Yazdani S, Simon AD, Kovar L, Wang W, Schwartz A, Rabbani LE 1997 Percutaneous interventions alter the hemostatic profile of patients with unstable versus stable angina. J Am Coll Cardiol 30:1284-1287
19. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH 1993 Endogenous tissue-type plasminogen activator and risk of MI. Lancet 341:1165-1168
20. Lijnen HR, Collen D 1996 Impaired fibrinolysis and the risk for coronary heart disease. Circulation 94:2052-2054
21. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK 1995 Association of fibrinolytic parameters with early atherosclerosis: the ARIC study. Circulation 91:284-290
22. Cortellaro M, Cofrancesco E, Boschetti C, Mussoni L, Donati MD, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G 1993 Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients: a case control study. Arterioscler Thromb 13:1412-1417
23. Scarabin PY, Plu-Bureau G, Bara L, Bonithon-Kopp C, Guize L, Samama MM 1993 Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thromb Haemost 70:584-587
24. Gebara OC, Mittleman MA, Sutherland P, Lipinska I, Matheney T, Xu P, Welty FK, Wilson PW, Levy D, Muller JE 1995 Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring study. Circulation 91:1952-1958
25. Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGoverrt PG, Shimakawa T, Chambless LE, Wu KK 1996 Relation of hormone replacement therapy to measures of plasma fibrinolytic activity: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 93:1970-1975
26. Gilabert J, Estelles A, Cano A, Espana F, Barrachina R, Grancha S, Aznar J, Tortajada M 1995 The effect of estrogen replacement therapy with or without progesterone on the fibrinolytic system and coagulation inhibitors in post-menopausal status. Am J Obstet Gynecol 173:1849-1854
27. Siegbahn A, Odlind V, Hedner U, Venge P 1989 Coagulation and fibrinolysis during the normal menstrual cycle. Ups J Med Sci 94:137-152
28. De Souza C, Jones PP, Seals DR 1998 Physical activity status and adverse age related differences in coagulation and fibrinolytic factors in women. Arterioscler Thromb Vasc Biol 18:362-368
29. Giannattasio C, Failla M, Grappiolo A, Stella ML, Bo AD, Colombo M, Mancia G 1999 Fluctuations of radial artery distensibility throughout the menstrual cycle. Arterioscler Thromb Vasc Biol 19:1925-1929
30. Westerman RA, Kingwell BA, Paige J, Blombery PA, Sudhir K, Komesaroff PA 2000 Variations in endothelial function and arterial compliance during the menstrual cycle. J Clin Endocrinol Metab 86:5389-5395
31. Hashimoto M, Akishita M, Eto M, Ishikawa M, Kozaki K, Toba K, Sagara Y, Taketani Y, Orimo H, Ouchi Y 1995 Modulation of endothelium-dependent flow-mediated dilatation of the brachial artery by sex and menstrual cycle. Circulation 92:3431-3435
32. Kawano H, Motoyama T, Kugiyama K, Hirashima O, Ohgushi M, Yoshimura M, Ogawa H, Okumura K, Yasue H 1996 Menstrual cyclic variation of endothelium dependent vasodilation of the brachial artery: possible role of estrogen and nitric oxide. Proc Assoc Am Physicians 108:473-480
33. English JL, Jacobs LO, Green G, Andrews TC 1998 Effect of the menstrual cycle on endothelium-dependent vasodilation of the brachial artery in normal young women. Am J Cardiol 82:256-258
34. Kawano H, Motoyama T, Ohgushi M, Kugiyama K, Ogawa H, Yasue H 2001 Menstrual cyclic variation of myocardial ischemia in premenopausal women with variant angina. Ann Intern Med 135:977-981
35. Muesing RA, Forman MR, Graubard BI, Beecher GR, Lanza E, McAdam PA, Campbell WS, Olson BR 1996 Cyclic changes in lipoprotein and apolipoprotein levels during the menstrual cycle in healthy premenopausal women on a controlled diet. J Clin Endocrinol Metab 81:3599-3603
36. Agrawal R, Conway GS, Sladkevicius P, Payne NN, Bekir J, Campbell S, Tan SL, Jacobs HS 1999 Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow. Clin Endocrinol (Oxf) 50:101-106
37. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM 1993 The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268:10739-10745
38. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A 1995 Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855
39. Leander K, Wiman B, Hallqvist J, Sten-Linder, de Raire U 2003 PAI-1 level and the PAI-1 4G/5G polymorphism in relation to risk of non-fatal myocardial infarction. Thromb Haemost 89:1064-1071
40. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP 1995 The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 74:837-884
41. Grancha S, Estelles A, Tormo G, Falco C, Gilabert J, Espana F, Cano A, Segui R, Aznar J 1999 Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and increased PAI-1 circulating levels in postmenopausal women with coronary artery disease. Thromb Haemost 81:516-521
42. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Miletich JP 1997 Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of U.S. men. Circulation 95:59-62
43. Hindorff LA, Schwartz SM, Siscovick DS, Psaty BM, Longstreth Jr WT, Reiner AP 2002 The association of PAI-1 promoter 4G/5G insertion/deletion polymorphism with myocardial infarction and stroke in young women. J Cardiovasc Risk 9:131-137